Roche’s Tecentriq + CT (abraxane and carboplatin) Receive the US FDA’s Approval for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

 Roche’s Tecentriq + CT (abraxane and carboplatin) Receive the US FDA’s Approval for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Roche’s Tecentriq + CT (abraxane and carboplatin) Receive the US FDA’s Approval for the initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Shots:

  • The approval is based on P-III IMpower130 study assessing Tecentriq + CT vs CT as monothx. in 681 chemotherapy-naïve patients with stage IV metastatic non-sq NSCLC with no EGFR or ALK genomic tumor aberrations
  • The P-III IMpower130 study results: OS (18.6 vs 13.9 mos.); PFS (7.2 vs 6.5 mos.); safety profile is consistent with the profile; no new safety signals were observed
  • Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptor and is approved in multiple countries including the US and EU as both monothx. and combination therapy for NSCLC and SCLC, types of m-UC and in PD-L1+ m-triple-negative BC

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Forbes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post